BYD-AUTO
12.1.2023 15:03:33 CET | Business Wire | Press release
BYD, the global leading new energy vehicle (NEV) manufacturer, presented its new luxury model BYD Seal and the limited edition of BYD ATTO 3 in its iconic color Forest Green at the Indian Auto Expo 2023. BYD Seal, whose sales have exceeded 50,000 within 5 months in China, is planned to be launched in India by Q4 2023. As the All-New e6 and BYD ATTO 3 are already available in the local market, BYD Seal will be the third passenger EV released in India within two years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005445/en/
Speech by Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles, BYD India (Photo: Business Wire)
At the Auto Expo 2023, BYD’s display space is sectioned into 4 zones, which showcase not only its current and new vehicle products but also technological innovations that substantially enhance the performance and safety of vehicles. These newly-unveiled products and innovation displays echo the Indian-specific theme at the convention: Technological Innovations For A Better Life.
BYD SEAL
BYD Seal is one of BYD’s latest luxury sedans equipped with its renowned EV platform (e-Platform 3.0) and revolutionary ultra-safe Blade Battery. Also, it is the first vehicle equipped with CTB (cell to body) technology, substantially upgrading the vehicle’s safety, stability, and handling, giving the vehicle an overall finer performance.
CTB-supported BYD Seal can withstand the 50-ton heavy-duty truck rolling test. Via the integration of battery and body, the torsional stiffness of the whole vehicle has doubled to above 40,500 N.m/°. The safety of the interior structure of the vehicle is increased by 50% for the front impact and by 45% for the side impact. Also, as CTB technology makes it possible for BYD Seal to have an ideal 50:50 axle load distribution, the vehicle passed the moose test at a record speed of 83.5km/h. With its low-lying design, the aero drag coefficient reached as low as 0.219cd, helping BYD Seal hit 100 km/h in 3.8 seconds. The model also has an ultra-long range of up to 700 km on a single charge, reducing the range anxiety of EVs.
BYD ATTO 3 Limited Edition
At the event, the Limited Edition of BYD ATTO 3 in the exclusive color of Forest Green, also adopts the e-Platform 3.0 and the ultra-safe Blade Battery. Only 1,200 units of this Limited Edition will be available in India at Rs. 34.49 lakhs (ex-showroom).
BYD ATTO 3, with an NEDC-certified range of 480 km and ARAI test range of 521 km, was launched in India in November 2022 for Rs. 33.99 lakhs and garnered 1,500 bookings to date, gaining good traction among customers. BYD ATTO 3 received a five-star safety rating from Euro NCAP, Europe’s leading independent safety assessment program. The E-SUV boasts an 8-year or 1.6 lakh kilometer (whichever comes earlier) warranty for the battery and a similar 8-year or 1.5 lakh kilometer warranty for the motor and motor controller. Besides, BYD offers a 6-year or 1.5 lakh kilometer basic warranty.
Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles of BYD India, said: “The Indian Auto Expo is an extremely significant platform for us, and we are pleased to be able to showcase our products and technologies through our technological innovations for a better life. With the unveiling of the electric luxury sedan BYD Seal, the launch of the Limited Edition of BYD ATTO 3, and the display of the Blade Battery, e-Platform 3.0, we resonate our commitment to contribute to the growth of the Indian electric vehicle segment with EV technologies.”
Within a year, BYD has expanded its network to 24 showrooms across 21 cities in India and will double the presence to 53 showrooms within 2023. “Next year, we plan to sell 15,000 units of BYD ATTO 3 and All-New e6 with a long-term vision to take up 40% of the Indian EV market by 2030. The bookings of BYD ATTO 3 have been encouraging, and we are all set to start the first deliveries from January 2023,” added Mr. Gopalakrishnan.
In 2022, BYD's cumulative sales of passenger vehicles were over 1.86 million units, a year-on-year increase of 155.1%. So far, BYD has sold more than 3.37 million new energy vehicles. With its expanding global presence, BYD is working towards its initiative of “Cool the Earth by 1 °C.”
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom